Literature DB >> 3740929

Neuroleptic malignant syndrome.

A Moore, N V O'Donohoe, H Monaghan.   

Abstract

A case of the neuroleptic malignant syndrome, an idiosyncratic response to neuroleptic drugs, is described. Symptoms persisted for eight weeks. The stopping of neuroleptics and general supportive measures are the mainstay of treatment. Failure to recognise this syndrome can lead to morbidity and death.

Entities:  

Mesh:

Year:  1986        PMID: 3740929      PMCID: PMC1777914          DOI: 10.1136/adc.61.8.793

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  6 in total

1.  [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses].

Authors:  J DELAY; P PICHOT; T LEMPERIERE; B ELISSALDE; F PEIGNE
Journal:  Ann Med Psychol (Paris)       Date:  1960-01       Impact factor: 0.380

2.  Lithium carbonate, haloperidol, and irreversible brain damage.

Authors:  W J Cohen; N H Cohen
Journal:  JAMA       Date:  1974-12-02       Impact factor: 56.272

3.  Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report.

Authors:  D J Coons; F J Hillman; R W Marshall
Journal:  Am J Psychiatry       Date:  1982-07       Impact factor: 18.112

4.  The neuroleptic malignant syndrome.

Authors:  R A Smego; D T Durack
Journal:  Arch Intern Med       Date:  1982-06

5.  Beneficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: a report of two cases.

Authors:  M Goulon; P de Rohan-Chabot; D Elkharrat; P Gajdos; C Bismuth; F Conso
Journal:  Neurology       Date:  1983-04       Impact factor: 9.910

6.  The neuroleptic malignant syndrome.

Authors:  S N Caroff
Journal:  J Clin Psychiatry       Date:  1980-03       Impact factor: 4.384

  6 in total
  1 in total

Review 1.  The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis.

Authors:  Melissa Lau Moon Lin; Paula D Robinson; Jacqueline Flank; Lillian Sung; L Lee Dupuis
Journal:  Drug Saf       Date:  2016-06       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.